Table of Contents
- Trial overview
- Who was studied
- What was tested
- Study phase and status
- Main endpoint
- What the results aim to show
Trial overview
The trial data provided here describe one interventional study, which means researchers assigned study treatments to participants rather than only observing them.[1] The study looked at smoking cessation, which means helping people stop smoking.[1]
The study title was Use of electronic cigarettes for smoking cessation, and it included Varenicline as a reference treatment for comparison.[1] The brief summary says the study aimed to assess the efficacy of electronic cigarettes with nicotine compared with electronic cigarettes without nicotine and with the licensed smoking cessation medication Varenicline.[1]
Who was studied
The trial targeted smokers smoking at least 10 cigarettes/day in the past year.[1] This means the study focused on people with regular smoking habits, not occasional smokers.[1]
The provided data do not list other eligibility details, so the main known target group is this smoking population.[1]
What was tested
The study compared three approaches: electronic cigarettes containing nicotine, electronic cigarettes without nicotine, and Varenicline as the reference medication.[1] A placebo version of CHAMPIX was also listed, which means an inactive comparison treatment was used in the trial design.[1]
Because the trial focused on smoking cessation, the comparison was meant to show which approach helped people stay smoke-free more effectively.[1]
Study phase and status
This was a Phase 3 trial.[1] Phase 3 studies usually test a treatment in a larger group of people to better understand how well it works in real study conditions.[1]
The study status was Suspended.[1] In simple terms, this means the trial was stopped for now and was not continuing as planned in the source data.[1]
Main endpoint
The main endpoint was the continuous smoking abstinence rate during the last 4 weeks of a 3-month treatment period.[1] An endpoint is the main result researchers measure to judge whether a study treatment is working.[1]
In patient terms, this endpoint asks whether people stayed smoke-free without interruption during the last month of treatment.[1]
What the results aim to show
The study was designed to compare Varenicline with other smoking cessation approaches, especially electronic cigarettes with and without nicotine.[1] The goal was to evaluate whether these approaches could help people stop smoking, with the main focus on sustained abstinence.[1]
The enrolled number was planned at 650 participants, showing that this was meant to be a fairly large smoking cessation study.[1] No numerical results were provided in the source data, so this article only summarizes the study design and goals.[1]
